Trial Summary
The trial protocol does not specify if you must stop taking your current medications. However, there is a requirement for a 'washout period' (time without taking certain medications) from previous therapies before starting the study treatment.
Ivonescimab has shown safety and effectiveness as a treatment for advanced non-small cell lung cancer (NSCLC) in patients who have not previously received immunotherapy, suggesting potential benefits for other cancers like skin cancer.
12345Ivonescimab, also known as AK-112 or Evoximab, is a type of immune checkpoint inhibitor, which can cause skin-related side effects like rashes, itching, and vitiligo (loss of skin color in patches). These side effects are common with similar treatments and are generally considered manageable.
678910Ivonescimab is unique because it is a bispecific antibody that targets both PD-1 (a protein that helps cancer cells evade the immune system) and VEGF (a protein that promotes blood vessel growth in tumors), potentially enhancing the immune response against skin cancer.
35111213Eligibility Criteria
This trial is for adults over 18 with advanced skin cancer (cSCC) that can't be removed or has spread, and who didn't respond to anti-PD-1 therapy. They should have a life expectancy of at least 3 months, manageable blood pressure on up to one medication, and agree to use contraception. People with certain medical conditions, previous severe reactions to PD-1 inhibitors, active infections requiring IV antibiotics, or uncontrolled illnesses are excluded.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Locally advanced or metastatic non-squamous NSCLC